Q3 FY25 Financial Performance - Revenue reached $203 million, a decrease of 3% year-over-year[7, 9] - Non-GAAP gross margin improved to 34%, a 100 bps increase year-over-year[7, 9] - Non-GAAP EPS increased to $0.18, a 29% increase year-over-year[7, 10] - Adjusted EBITDA increased to $29 million, a 27% increase year-over-year[13] - The company paid off $200 million in convertible notes on June 2[7] Balance Sheet and Cash Flow - Cash, cash equivalents, and marketable securities totaled $153 million[7, 8] - Adjusted EBITDA for the trailing twelve months (TTM) was $110 million[31] - Net debt leverage (TTM) was 20x[31] Segment and Geographic Revenue Mix - Medical segment revenue was $142 million[19, 21] - Industrial segment revenue was $61 million[19, 21] - Revenue from the Americas was $71 million[20, 22] Q4 FY25 Guidance - Revenue is projected to be between $210 million and $230 million[34] - Non-GAAP EPS is expected to be between $010 and $030[34]